Bio-Techne Reports Q1 Fiscal 2027 Results and Advances Merck KGaA Merger

Bio-Techne reported fiscal Q1 2027 adjusted EPS of $0.44, up 4.8% year over year and 10% above the Zacks consensus estimate. Net sales rose 5% on a reported basis and 7% organically to $299.7 million, exceeding analyst expectations. Shareholders approved the merger agreement with Merck KGaA, valued at approximately $11.3 billion. Bio-Techne also declared a quarterly dividend of $0.08 per share, payable November 23, 2026, if the merger has not closed by then.